Residual HIV-1 replication may impact immune recovery in patients on first-line lopinavir/ritonavir monotherapy | Zendy

Tú-Anh Tran | Zendy; Jade Ghosn | Zendy; Véronique Avettand-Fènoël | Zendy; Houria HendelChavez | Zendy; Marie-Ghislaine de Goër de Herve | Zendy; Isabelle Cohen-Codar | Zendy; Christine Rouzioux | Zendy; JeanFrançois Delfraissy | Zendy; Yassine Taoufik | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Residual HIV-1 replication may impact immune recovery in patients on first-line lopinavir/ritonavir monotherapy

Author(s) -

Tú-Anh Tran,

Jade Ghosn,

Véronique Avettand-Fènoël,

Houria HendelChavez,

Marie-Ghislaine de Goër de Herve,

Isabelle Cohen-Codar,

Christine Rouzioux,

JeanFrançois Delfraissy,

Yassine Taoufik

Publication year - 2015

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkv138

Subject(s) - lopinavir/ritonavir , ritonavir , lopinavir , zidovudine , lamivudine , virology , viral load , medicine , cd8 , immunology , combination therapy , pharmacology , oncology , immune system , virus , viral disease , antiretroviral therapy , hepatitis b virus

Antiretroviral combination therapy raises issues of long-term adherence and toxicity. Initial treatment simplification based on single-drug therapy was investigated in the MONARK trial, which compared first-line lopinavir/ritonavir monotherapy (arm A) with first-line lopinavir/ritonavir + zidovudine/lamivudine tritherapy (arm B). The MONARK trial is registered as a randomized trial at clinical trials.gov under identifier NCT 00234923.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research